Effects of salvianolic acid A on β-amyloid mediated toxicity in Caenorhabditis elegans model of Alzheimer's disease
Keywords:
Salvianolic acid A, Alzheimer’s disease, β-amyloid, C. elegansAbstract
Alzheimer’s disease (AD) is a brain disease attributed to the accumulation of extracellular senile plaques comprising β-amyloid peptide (Aβ). In this study, a transgenic Caenorhabditis elegans (C. elegans) containing the human beta amyloid Aβ42 gene which exhibited paralysis when expressed, was used to study the anti-paralysis effect of salvianolic acid A. Various concentrations ranging from 1 μg/ml to 100 μg/ml of salvianolic acid A were tested which exhibited the highest effect on the worm at the concentration of 100 μg/ml. For anti-aggregation effect, 14 μg/ml of salvianolic acid A (within 4 mg/ml of Danshen) showed a significant level of inhibition of the formation of Aβ fibrils. An amount of 100 μg/ml of salvianolic acid A had the potential in reducing the reactive oxygen species (ROS) but did not totally obliterate the ROS production in the worms. Salvianolic acid A was found to delay the paralysis of the transgenic C. elegans, decrease Aβ42 aggregation and decrease Aβ-induced oxidative stress.
References
Walsh, D.M. and D.B. Teplow, Alzheimer's disease and the amyloid β-protein, in Progress in molecular biology and translational science. 2012, Elsevier. p. 101-124.
Glenner, G.G. and C.W. Wong, Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and biophysical research communications, 1984. 122(3): p. 1131-1135.
Kang, J., et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987. 325(6106): p. 733.
Goate, A., et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991. 349(6311): p. 704.
Hardy, J.A. and G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992. 256(5054): p. 184-186.
Jia, Q., Y. Deng, and H. Qing, Potential therapeutic strategies for Alzheimer’s disease targeting or beyond β-amyloid: insights from clinical trials. BioMed research international, 2014. 2014.
Xu, J.-z., et al., Simultaneous detection of seven phenolic acids in Danshen injection using HPLC with ultraviolet detector. Journal of Zhejiang University SCIENCE B, 2008. 9(9): p. 728-733.
Lin, T.-J., K.-J. Zhang, and G.-T. Liu, Effects of salvianolic acid A on oxygen radicals released by rat neutrophils and on neutrophil function. Biochemical pharmacology, 1996. 51(9): p. 1237-1241.
Zhang, H., et al., Salvianolic acid A protects RPE cells against oxidative stress through activation of Nrf2/HO-1 signaling. Free Radical Biology and Medicine, 2014. 69: p. 219-228.
Yan, X., Dan Shen (Salvia miltiorrhiza) in Medicine. 2015: Springer.
McColl, G., et al., Utility of an improved model of amyloid-beta (Aβ 1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease. Molecular neurodegeneration, 2012. 7(1): p. 57.
Gutierrez-Zepeda, A., et al., Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC neuroscience, 2005. 6(1): p. 54.
Sola, I., et al., Multigram synthesis and in vivo efficacy studies of a novel multitarget anti-Alzheimer’s compound. Molecules, 2015. 20(3): p. 4492-4515.
Bharadwaj, P.R., et al., Aβ aggregation and possible implications in Alzheimer's disease pathogenesis. Journal of cellular and molecular medicine, 2009. 13(3): p. 412-421.
DaSilva, K.A., J.E. Shaw, and J. McLaurin, Amyloid-β fibrillogenesis: structural insight and therapeutic intervention. Experimental neurology, 2010. 223(2): p. 311-321.
Lorenzo, A. and B. Yankner, Amyloid Fibril Toxicity in Alzheimer's Disease and Diabetes a. Annals of the New York Academy of Sciences, 1996. 777(1): p. 89-95.
Azriel, R. and E. Gazit, Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide an experimental support for the key role of the phenylalanine residue in amyloid formation. Journal of Biological Chemistry, 2001. 276(36): p. 34156-34161.
Makin, O.S., et al., Molecular basis for amyloid fibril formation and stability. Proceedings of the National Academy of Sciences, 2005. 102(2): p. 315-320.
Porat, Y., A. Abramowitz, and E. Gazit, Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chemical biology & drug design, 2006. 67(1): p. 27-37.
Link, C.D., C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer’s disease. Experimental gerontology, 2006. 41(10): p. 1007-1013.
Link, C.D., et al., Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiology of aging, 2001. 22(2): p. 217-226.
Link, C.D., et al., Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer’s disease model. Neurobiology of aging, 2003. 24(3): p. 397-413.
Drake, J., C.D. Link, and D.A. Butterfield, Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid β-peptide (1–42) in a transgenic Caenorhabditis elegans model. Neurobiology of aging, 2003. 24(3): p. 415-420.
Yin, F., et al., Baicalin prevents the production of hydrogen peroxide and oxidative stress induced by Aβ aggregation in SH-SY5Y cells. Neuroscience letters, 2011. 492(2): p. 76-79.
Bastianetto, S., S. Krantic, and R. Quirion, Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini reviews in medicinal chemistry, 2008. 8(5): p. 429-435.
Cao, Y.Y., et al., Salvianolic acid A, a polyphenolic derivative from Salvia miltiorrhiza bunge, as a multifunctional agent for the treatment of Alzheimer’s disease. Molecular diversity, 2013. 17(3): p. 515-524.
Back, P., B.P. Braeckman, and F. Matthijssens, ROS in aging Caenorhabditis elegans: damage or signaling? Oxidative medicine and cellular longevity, 2012. 2012.
Yanase, S. and N. Ishii, Cloning of the oxidative stress-responsive genes in Caenorhabditis elegans. Journal of radiation research, 1999. 40(1): p. 39-47.
Rangsinth, P., et al., Leaf extract of Caesalpinia mimosoides enhances oxidative stress resistance and prolongs lifespan in Caenorhabditis elegans. BMC complementary and alternative medicine, 2019. 19(1): p. 164.
Tsai, M.-K., Y.-L. Lin, and Y.-T. Huang, Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicology and applied pharmacology, 2010. 242(2): p. 155-164.
Downloads
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
